BEIJING, April 26, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2015 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2015 on April 25, 2016. The Annual Report on Form 20-F is now available on the Company's website under SEC Filings in the Investor Relations section.
The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2015 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 entered the commercialization production phrase and will be launched into the market by the end of first half of 2016. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the Philippines, and was recently granted a license to commercialize its influenza vaccine in Guatemala. For more information, please visit the Company's website at www.sinovac.com.
Contact
Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871Fax: +86-10-6296-6910 Email: [email protected]
ICR Inc.Bill ZimaU.S: 1-646-308-1707Email: [email protected]
Advertisement
The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2015 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form.
Advertisement
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 entered the commercialization production phrase and will be launched into the market by the end of first half of 2016. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan, Bangladesh, Chile and the Philippines, and was recently granted a license to commercialize its influenza vaccine in Guatemala. For more information, please visit the Company's website at www.sinovac.com.
Contact
Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279-9871Fax: +86-10-6296-6910 Email: [email protected]
ICR Inc.Bill ZimaU.S: 1-646-308-1707Email: [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-files-2015-annual-report-on-form-20-f-300257431.html
SOURCE Sinovac Biotech Co., Ltd.
